.png?itok=-ptHSluh&q=Alnylam%20Pharmaceuticals&ck=D7D6446024D2FC67F131D351494F4801&idpp=rc&idpview=singleimage&form=rc2idp "Alnylam Pharmaceuticals1")
Ionis Pharmaceuticals
Search results
Alnylam is a leading biotech company that develops RNAi therapeutics to silence genes that cause or contribute to human disease. Learn about its science, pipeline, patients, and corporate responsibility.
- The Science of RNAi
How siRNAs Work. When the siRNA duplex is delivered into the...
- Delivery Platforms
Our Science. DELIVERY PLATFORMS. Our RNA interference (RNAi)...
- Therapeutic Areas
Learn about Alnylam's pipeline of investigational RNAi...
- Clinical Trials
Alnylam Clinical Trial Information Line...
- Scientific Advisory Board
The following content may not be associated with Alnylam...
- Intellectual Property
Our Science. INTELLECTUAL PROPERTY. Alnylam protects its...
- Capella (Scientific Presentations)
We presented additional positive interim results for an...
- Product Listing
Find information about Alnylam's pharmaceutical products:...
- The Science of RNAi
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam is a biopharmaceutical company that develops RNAi (RNA interference) medicines for genetic and other diseases. Learn about its pipeline of investigational RNAi therapeutics, clinical trials, and strategic therapeutic areas.
Alnylam is a biopharmaceutical company that develops RNAi-based medicines for genetic and other diseases. Learn about its history, science, vision, mission, and values.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Get the latest Alnylam Pharmaceuticals, Inc. (ALNY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Oct 25, 2023 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the...
